JP2023540037A - ＳＡＲＳ－ＣｏＶ－２を標的にする抗原結合分子 - Google Patents

ＳＡＲＳ－ＣｏＶ－２を標的にする抗原結合分子 Download PDF

Info

Publication number
JP2023540037A
JP2023540037A JP2023513355A JP2023513355A JP2023540037A JP 2023540037 A JP2023540037 A JP 2023540037A JP 2023513355 A JP2023513355 A JP 2023513355A JP 2023513355 A JP2023513355 A JP 2023513355A JP 2023540037 A JP2023540037 A JP 2023540037A
Authority
JP
Japan
Prior art keywords
polypeptide
seq
cov
amino acid
sars
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023513355A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022047033A5 (https=
JP2023540037A5 (https=
Inventor
ゲボルグ グリゴリアン，
ジョン イングラハム，
Original Assignee
フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー filed Critical フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー
Publication of JP2023540037A publication Critical patent/JP2023540037A/ja
Publication of JPWO2022047033A5 publication Critical patent/JPWO2022047033A5/ja
Publication of JP2023540037A5 publication Critical patent/JP2023540037A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023513355A 2020-08-26 2021-08-26 ＳＡＲＳ－ＣｏＶ－２を標的にする抗原結合分子 Pending JP2023540037A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063070707P 2020-08-26 2020-08-26
US63/070,707 2020-08-26
PCT/US2021/047757 WO2022047033A1 (en) 2020-08-26 2021-08-26 Antigen binding molecules targeting sars-cov-2

Publications (3)

Publication Number Publication Date
JP2023540037A true JP2023540037A (ja) 2023-09-21
JPWO2022047033A5 JPWO2022047033A5 (https=) 2024-08-26
JP2023540037A5 JP2023540037A5 (https=) 2024-08-26

Family

ID=77897739

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023513355A Pending JP2023540037A (ja) 2020-08-26 2021-08-26 ＳＡＲＳ－ＣｏＶ－２を標的にする抗原結合分子

Country Status (9)

Country Link
US (1) US11987616B2 (https=)
EP (1) EP4204446A1 (https=)
JP (1) JP2023540037A (https=)
KR (1) KR20230058434A (https=)
CN (1) CN116528897A (https=)
AU (1) AU2021332340A1 (https=)
CA (1) CA3188716A1 (https=)
IL (1) IL300720A (https=)
WO (1) WO2022047033A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL299631A (en) 2020-07-06 2023-03-01 Flagship Pioneering Innovations Vi Llc Antigen binding molecules targeting sars-cov-2
CA3183367A1 (en) 2020-07-06 2022-01-13 Gevorg GRIGORYAN Antigen binding molecules targeting sars-cov-2
KR20230058434A (ko) 2020-08-26 2023-05-03 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 SARS-CoV-2를 표적으로 하는 항원 결합 분자
AR123469A1 (es) * 2020-09-10 2022-12-07 Bighat Biosciences Inc DOMINIOS DE UNIÓN A LA GLICOPROTEÍNA ESPICULAR DEL SARS-CoV(-2) Y POLIPÉPTIDOS QUE LOS COMPRENDEN Y USO DE ESTOS
AU2023265164A1 (en) 2022-05-06 2024-11-21 Generate Biomedicines, Inc. Antigen binding molecules targeting sars-cov-2
JP2025537301A (ja) 2022-11-13 2025-11-14 ジェネレイト バイオメディシンズ， インコーポレイテッド Ｓａｒｓ－ｃｏｖ－２を標的とする抗原結合分子
CN117442594A (zh) * 2023-04-20 2024-01-26 厦门大学 化合物在诊断与治疗新型冠状病毒感染中的应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2531684C (en) 2003-07-22 2014-03-11 Crucell Holland B.V. Binding molecules against sars-coronavirus and uses thereof
CA2548942C (en) 2003-12-05 2013-10-15 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Anti-sars monoclonal antibodies
EP1812067B1 (en) 2004-11-11 2012-03-21 Crucell Holland B.V. Compositions against sars-coronavirus and uses thereof
DK1817340T3 (da) 2004-11-12 2012-08-13 Xencor Inc Fc-varianter med ændret binding til fcrn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
RU2529951C2 (ru) 2007-12-26 2014-10-10 Ксенкор, Инк. ВАРИАНТЫ Fc С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ C FcRn
PT3031913T (pt) 2013-08-09 2019-05-31 Astellas Pharma Inc Novo anticorpo anti-receptor de tslp humana
CA2962731A1 (en) 2014-10-01 2016-04-07 Medimmune Limited Binding proteins specific for lox1 and uses thereof
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
JP7695698B2 (ja) 2019-01-14 2025-06-19 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 細胞内部移行をモジュレートするための組成物および方法
AR120698A1 (es) 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
JP2023512684A (ja) 2020-02-03 2023-03-28 ヴィア・バイオテクノロジー・インコーポレイテッド Ｓａｒｓ－ｃｏｖ－２に対する抗体およびそれを使用する方法
WO2021156490A2 (en) * 2020-02-06 2021-08-12 Vib Vzw Corona virus binders
SG11202110145SA (en) 2020-02-26 2021-10-28 Vir Biotechnology Inc Antibodies against sars-cov-2 and methods of using the same
CN115515976A (zh) 2020-03-19 2022-12-23 帝国理工学院创新有限公司 冠状病毒抗体
US11028167B1 (en) 2020-03-23 2021-06-08 Centivax, Inc. Anti-SARS-Cov-2 antibodies derived from 3bgf
CR20220552A (es) 2020-04-02 2023-01-17 Regeneron Pharma Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
WO2021203053A1 (en) 2020-04-03 2021-10-07 Vir Biotechnology, Inc. Immunotherapy targeting a conserved region in sars coronaviruses
US20230348571A1 (en) 2020-04-06 2023-11-02 Vanderbilt University Cross-reactive coronavirus antibodies and uses thereof
TW202204397A (zh) 2020-04-10 2022-02-01 美商亞得捷歐治療公司 對冠狀病毒s蛋白質具特異性之化合物及其用途
JP2023523549A (ja) 2020-04-14 2023-06-06 ヴィア・バイオテクノロジー・インコーポレイテッド ＳＡＲＳ－ＣｏＶ－２に対する抗体およびそれを使用する方法
CN115461364B (zh) 2020-04-28 2025-12-16 北京大学 一种抗新型冠状病毒的单克隆抗体及其应用
MX2022013886A (es) 2020-05-08 2022-11-30 Vir Biotechnology Inc Anticuerpos contra coronavirus de tipo 2 causante del sindrome respiratorio agudo severo (sars-cov-2).
WO2021247925A1 (en) 2020-06-03 2021-12-09 Vir Biotechnology, Inc. Structure-guided immunotherapy against sars-cov-2
CA3183367A1 (en) 2020-07-06 2022-01-13 Gevorg GRIGORYAN Antigen binding molecules targeting sars-cov-2
IL299631A (en) 2020-07-06 2023-03-01 Flagship Pioneering Innovations Vi Llc Antigen binding molecules targeting sars-cov-2
WO2022015573A2 (en) 2020-07-13 2022-01-20 President And Fellows Of Harvard College Sars-cov-2 antigen-binding proteins and uses thereof
EP4188951A4 (en) 2020-07-27 2024-08-28 IGM Biosciences, Inc. Multimeric coronavirus binding molecules and uses thereof
WO2022046888A1 (en) 2020-08-25 2022-03-03 Target Discovery Merger Sub II, LLC Sars-cov-2 associated antibody compositions and methods of use
KR20230058434A (ko) 2020-08-26 2023-05-03 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 SARS-CoV-2를 표적으로 하는 항원 결합 분자
JP2024502046A (ja) 2020-12-29 2024-01-17 バル－チャム，リミティド パートナーシップ Ｃｏｖｉｄ－１９に対する中和モノクローナル抗体
WO2022159685A2 (en) 2021-01-22 2022-07-28 Vanderbilt University Sars-cov-2 coronavirus antibodies and uses thereof
WO2022204202A1 (en) 2021-03-23 2022-09-29 Vir Biotechnology, Inc. Antibodies that bind to multiple sarbecoviruses
CA3218489A1 (en) 2021-05-24 2022-12-01 Vir Biotechnology, Inc. Engineered polypeptides
US20240270797A1 (en) 2021-06-23 2024-08-15 Cz Biohub Sf, Llc Coronavirus neutralizing compositions and associated methods
TW202315895A (zh) 2021-08-27 2023-04-16 瑞士商休曼生物醫藥股份公司 經工程化的組成物
EP4147716A1 (en) 2021-09-10 2023-03-15 Samatva Research Corporation Anti-virus moiety immobilised in a matrix
AU2023265164A1 (en) 2022-05-06 2024-11-21 Generate Biomedicines, Inc. Antigen binding molecules targeting sars-cov-2

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ACCESSION NO. MT350284.1, GENBANK [ONLINE], vol. [検索日 2025.07.29], JPN6025031641, May 2020 (2020-05-01), ISSN: 0005783698 *
DANIEL WRAPP ET AL., CELL, vol. 181, no. 5, JPN6025031640, May 2020 (2020-05-01), pages 1005 - 1015, ISSN: 0005783697 *

Also Published As

Publication number Publication date
EP4204446A1 (en) 2023-07-05
US11987616B2 (en) 2024-05-21
AU2021332340A9 (en) 2024-05-09
CA3188716A1 (en) 2022-03-03
CN116528897A (zh) 2023-08-01
AU2021332340A1 (en) 2023-10-05
US20230287089A1 (en) 2023-09-14
KR20230058434A (ko) 2023-05-03
WO2022047033A1 (en) 2022-03-03
IL300720A (en) 2023-04-01

Similar Documents

Publication Publication Date Title
US11987616B2 (en) Antigen binding molecules targeting SARS-CoV-2
US11981725B2 (en) Antigen binding molecules targeting SARS-CoV-2
WO2021244089A1 (zh) 新型冠状病毒（sars-cov-2）刺突蛋白结合分子及其应用
US12473560B2 (en) Antigen binding molecules targeting SARS-CoV-2
KR102748987B1 (ko) 사스-코로나바이러스-2에 특이적으로 결합하는 항체 및 그의 용도
EP3970798A1 (en) Sars-cov-2-nanobodies
US20240398911A1 (en) Engineered receptors and monoclonal antibodies for cronaviruses and uses thereof
CN110612310B (zh) 抗cldn-5抗体及含有该抗体的药物
CN116547005A (zh) 靶向SARS-CoV-2的抗原结合分子
CN118812704B (zh) 一种抗新型冠状病毒的四价中和抗体及其应用
CN116635410A (zh) 靶向SARS-CoV-2的抗原结合分子
US20240043506A1 (en) Sars-cov-2 antibodies
US11174322B2 (en) Antibodies and peptides to treat HCMV related diseases
WO2025230768A1 (en) Compositions and methods related to coronavirus therapies
IL325269A (en) Antibodies specific for MHC class I chain-associated protein A (MICA) and their uses
TW202309069A (zh) 糖鏈修飾rbd及其用途
CN121773139A (zh) 抗c-MET纳米抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240816

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240816

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260408